Tissue Repair Ltd (ASX:TRP)
Tissue Repair Ltd (ASX:TRP) is a clinical stage biopharmaceutical company developing advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures, with the potential for development of related technologies.
The Company has isolated a unique active ingredient that is designed for wound healing and which is delivered topically. The biologically active pharmaceutical ingredient (API) behaves like a decoy cell that simulates a yeast infection, resulting in the stimulation of the bodys own wound repair pathways. This unique active ingredient provides Tissue Repair with a platform with which to develop a number of products that have the potential to treat a broad range of conditions across the wound care and cosmetic procedure aftercare markets.
Tissue Repair is in the final stages of completing its Phase II program for its chronic wound product, TR-987, having completed the field activity and preliminary analysis of Phase IIB clinical trials in 2020. Tissue Repair is planning to commence pivotal Phase III trials for TR-987 in 2022, subject to FDA approval.
Tissue Repair is also planning to launch its cosmeceutical product, TR Pro+, in the Australian market in 2022. TR Pro+ is a cosmeceutical post-procedure gel to be used following certain minimally invasive cosmetic procedures.